4DMedical stock
Price history
+48.45% over the period1 year: from $1.46 (November 20, 2025) to $2.16 (November 20, 2026), +48.45%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $2.16 |
| October 30, 2026 | $2.44 |
| September 30, 2026 | $4.25 |
| August 31, 2026 | $3.42 |
| July 31, 2026 | $3.63 |
| June 30, 2026 | $4.53 |
| May 29, 2026 | $3.97 |
| April 30, 2026 | $4.01 |
| March 31, 2026 | $5.56 |
| February 27, 2026 | $4.00 |
| January 30, 2026 | $3.17 |
| December 31, 2025 | $3.93 |
| November 28, 2025 | $1.71 |
| November 20, 2025 | $1.46 |
At a glance
The company
Develop non-invasive respiratory imaging software and solutions for lung health assessment and drug development
Latest results
Quarter to June 30, 2026 · EPS -$0.07 (estimate -$0.03)
Next event
TickerLandia's take on 4DMedical
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−71.39% from the 52-week high
Analysts · 3 analysts
Average target$4.17+92.90% vs. price
Buy 1 · Hold 2 · Sell 0
TickerLandia Fingerprint: 4DMedical
Compared with similar companies: very low earnings stability, very high growth, and very high risk.
Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high90
How much it costs relative to what it produces.
Metric Value Position in group Price/book 8.07 81 Price/sales 196.2 99 Profitabilitylow22
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 93.8% 97 Operating marginabove 100%: likely one-off items −813.7% 1 Net margin 0.0% 8 ROE −174.4% 3 ROA −15.6% 1 Earnings stabilityvery low2
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2,348.7% 1 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 2 Growthvery high97
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +114.19% 99 Earnings growth (year over year) +124.62% 96 Revenue growth (year over year) +42.30% 97 Financial strengthaverage45
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −0.34 6 Debt/equitycounts in reverse: lower means more financial strength 1.06 29 Current ratio 30.8 99 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak27
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −43.20% 4 Relative strength (6 months) −34.88% 10 1-year return +48.45% 89 Distance from 200-day average −45.65% 6 Riskvery high95
How much the price swings.
Metric Value Position in group Volatility (60 days) 94.9% 97 Beta (1 year) 2.37 94 Maximum drawdown (12 months) 68.7% 93
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
4DMedical is pricier than similar companies
4DMedical's Price/book: 7.58, +31% against the median of a group of 7 similar companies (5.80).
Compared with 7 similar companies
| Metric | 4DMedical | Position in the group | Band |
|---|---|---|---|
| Operating margin | -813.7% | Low | |
| ROE | -174.4% | Low | |
| Debt/equity | 1.06 | High | |
| Price/book | 7.58 | Middle | |
| Net margin | 0.0% | Middle |
Grey band: the middle half of the group; tick: the median; dot: 4DMedical. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$4.21M
Latest quarter · Q2 2026
Net income
-$50.3M
Latest quarter · Q2 2026
Quarterly net margin
-1,194.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $1.3B
- EPS
- -$0.38
- Volume
- 4.32M
- Daily trading
- €9.69M
- Dividend yield
- 0.00%
How 4DMedical is changing
All resultsRevenue grew 100.7% a year on average over the last 5 years
Operating margin rose from −6,202.5% to −813.7%
Shares outstanding up 109.8% in 5 years
Returns
4DMedical returns
$1,000 invested in 4DMedical 5 years ago, on November 22, 2021, would be worth $1,800 today: +80.00% in total, +12.49% per year. This is the price return only: dividends are excluded.
| Period | 4DMedical | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | −42.09% | −2.54% | $579 |
| 6 months | −34.15% | +1.13% | $659 |
| Year to date | −45.04% | −1.40% | $550 |
| 1 year | +48.45% | +0.47% | $1,485 |
| 3 years | +204.23% | +21.74% | $3,042 |
| 5 years | +80.00% | +16.86% | $1,800 |
Over the last 6 months it has done better than 25% of the stocks in the Technology sector.
Price only, without dividends. Calculate your investment
The chart in detail
4DMedical: technical analysis
4DMedical is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 68.2% below its all-time closing high ($6.80, April 10, 2026).
- Trend
- Downward
- RSI (14 sessions)
- 31
- Between 30 and 70
- vs 200-session average
- −45.65%
Support and resistance
Price areas where 4DMedical has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$3.64+68.29%4 touches, last on October 15, 2026
- Resistance$3.29+52.24%3 touches, last on September 11, 2026
- Resistance$3.03+40.43%3 touches, last on July 24, 2026
- Last price$2.16
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 2.37
- Volatility (60 sessions, annualised)
- 94.9%
- Largest fall in the last year
- −68.68%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
4DMedical: seasonality
Average monthly price change over 7 years
Over the last 7 years, the strongest month for 4DMedical has been September: +40.55% on average, positive in 4 years out of 7. The weakest has been February: −9.40% on average, positive in 2 years out of 6. November, the current month, has been positive in 2 years out of 6 (+10.92% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −8.07% | −13.82% | 2 of 6 |
| February | −9.40% | −15.28% | 2 of 6 |
| March | +1.46% | −1.42% | 2 of 6 |
| April | +21.05% | −7.92% | 2 of 6 |
| May | −6.08% | −5.54% | 1 of 6 |
| June | −8.83% | −10.20% | 1 of 6 |
| July | +3.58% | +1.49% | 3 of 6 |
| August | +19.97% | −3.56% | 2 of 6 |
| September | +40.55% | +14.48% | 4 of 7 |
| October | −4.75% | −7.51% | 3 of 7 |
| November | +10.92% | −1.08% | 2 of 6 |
| December | +16.79% | +1.44% | 3 of 6 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
4DMedical and its competitors
Pharmaceutical developers, clinical researchers and lung-health programmes in the United States and Australia are the core of the market served by 4DMedical Limited, a medical technology company that develops non-invasive respiratory imaging. Its range includes CT:VQ, a non-contrast post-processing technology, CAC for non-contrast cardiothoracic risk assessment, LDAi for automated detection of potential emphysema, and the XV Scanner, a lung function scanner. Its XV LVAS and CT LVAS software image lung airflow and regional lung function.
- Headquarters
- Carlton, Australia
- Employees
- 181
- Founded
- 2012
- Chief executive
- Andreas Fouras
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| 4DMedical4DX | $867.27M | -813.7% | — | −34.15% |
| XtalPi Holdings2228 | $3B | -124.6% | — | −39.24% |
| M32413 | $7.04B | 19.5% | 24.4 | +19.18% |
| Pro MedicusPME | $13.08B | 74.9% | 76.0 | +45.89% |
| DoximityDOCS | $5.13B | 27.1% | 39.9 | +44.66% |
| Tempus AITEM | $9.86B | -18.5% | — | +17.79% |
Same industry or related industries, similar size. Compare 4DMedical with its competitors · Full profile
